Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.
Dr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.
We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.
We spoke with Dr. Julie Brahmer about how survival rates are starting to improve with the use of nivolumab in non-small cell lung cancer.
We spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.
We spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.
We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.
Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.
Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.
We spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.